KBC Group NV Boosts Stake in Keros Therapeutics, Inc. (NASDAQ:KROS)

KBC Group NV raised its position in Keros Therapeutics, Inc. (NASDAQ:KROS) by 52.0% during the third quarter, HoldingsChannel.com reports. The firm owned 1,263 shares of the company’s stock after buying an additional 432 shares during the quarter. KBC Group NV’s holdings in Keros Therapeutics were worth $73,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after buying an additional 280 shares during the period. Values First Advisors Inc. acquired a new stake in shares of Keros Therapeutics in the third quarter worth $89,000. Ameritas Investment Partners Inc. raised its stake in shares of Keros Therapeutics by 14.5% in the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after acquiring an additional 324 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Keros Therapeutics during the 2nd quarter valued at $128,000. Finally, Victory Capital Management Inc. purchased a new stake in Keros Therapeutics during the 3rd quarter worth $216,000. 71.56% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

KROS has been the topic of several research reports. HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a research report on Thursday, November 7th. Jefferies Financial Group began coverage on Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating on the stock. Guggenheim began coverage on Keros Therapeutics in a report on Monday, September 23rd. They issued a “buy” rating and a $96.00 price target for the company. Wedbush reaffirmed an “outperform” rating and issued a $84.00 price objective on shares of Keros Therapeutics in a research report on Thursday, November 7th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Keros Therapeutics in a research report on Friday. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $88.89.

Keros Therapeutics Price Performance

NASDAQ KROS opened at $55.92 on Friday. The company has a market capitalization of $2.27 billion, a price-to-earnings ratio of -10.73 and a beta of 1.23. Keros Therapeutics, Inc. has a 12 month low of $27.31 and a 12 month high of $73.00. The company’s fifty day moving average price is $59.30 and its two-hundred day moving average price is $52.26.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The company had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business’s revenue was up 4750.0% on a year-over-year basis. During the same quarter last year, the firm earned ($1.33) earnings per share. As a group, analysts anticipate that Keros Therapeutics, Inc. will post -5.28 EPS for the current year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.